As a result of these findings of noncompliance, CMS proposed to impose the alternative sanctions of a CMP and a directed plan of correction. CMS explained that such inter-laboratory communication of PT results is prohibited under the CLIA regulations. CMS agreed with the state agency’s finding that Petitioner had communicated to Castle Medical LLC (Castle), a laboratory located in Smyrna, Georgia, the results Petitioner obtained by analyzing proficiency testing (PT) samples Castle had improperly referred to Petitioner. § 493.1441, which sets forth requirements for the laboratory director for laboratories performing high complexity testing. § 493.801, which governs the enrollment and testing of samples and 42 C.F.R. CMS stated that it had determined that Petitioner was noncompliant with two CLIA conditions of participation: 42 C.F.R. By letter dated May 30, 2017, CMS informed Petitioner that, based on the survey, it was proposing sanctions against Petitioner’s CLIA certificate. (state agency) conducted a complaint survey of Petitioner on March 10, 2017. The North Carolina Department of Health and Human Services CMS Brief (Br.) at 1 see also CMS Exhibit (Ex.) 2 at 4. Petitioner is a laboratory located in Research Triangle, North Carolina, that holds a CLIA certificate to perform high complexity testing. For the reasons set forth below, I grant CMS’s motion, deny Petitioner’s cross-motion, and sustain the penalties of a directed plan of correction and a civil money penalty (CMP) of $54,297 against Petitioner. Petitioner opposed CMS’s motion and cross-moved for summary judgment. (Petitioner), 1Īppeals the determination of the Centers for Medicare & Medicaid Services (CMS) to impose remedies against Petitioner under the Clinical Laboratory Improvement Amendments of 1988 (CLIA), 42 U.S.C. Laboratory Corporation of America Holdings, Inc. About DAB has sub items, about About DAB.Medicare Appeals Council (Council) Decisions.DAB Administrative Law Judge (ALJ) Decisions.DAB Decisions has sub items, about DAB Decisions.Alternative Dispute Resolution Services has sub items, about Alternative Dispute Resolution Services.Fully Integrated Duals Advantage (FIDA) Demonstration Project.Appeals to the Medicare Appeals Council (Council).National Coverage Determination Complaints.Appeals to DAB Administrative Law Judges (ALJs).Different Appeals at DAB has sub items, about Different Appeals at DAB.Medicare Operations Division (MOD) E-File.Filing an Appeal Online has sub items, about Filing an Appeal Online.Learn more about us at or follow us on LinkedIn and Twitter. Labcorp (NYSE: LH) reported revenue of $16 billion in FY2021. With over 75,000 employees, we serve clients in more than 100 countries. Through our unparalleled diagnostics and drug development capabilities, we provide insights and accelerate innovations to improve health and improve lives. Labcorp is a leading global life sciences company that provides vital information to help doctors, hospitals, pharmaceutical companies, researchers, and patients make clear and confident decisions. The webcast of the conference call will be archived and accessible through April 14, 2023, on the Labcorp Investor Relations website. and Canada, or 1-40 internationally, using the conference ID 2386657. EDT on May 12, 2022, by dialing 1-85 within the U.S. Īn audio replay of the conference call will be available from 1 p.m. In addition, a real-time webcast of the conference call will be available on the Labcorp Investor Relations website. and Canada, or 1-63 internationally, using the conference ID 2386657. Interested parties can access the conference call by dialing 1-87 within the U.S. The earnings press release and accompanying financial information will be posted on the Labcorp Investor Relations website. The company will host a conference call and webcast beginning at 9 a.m. Investors: Chas Cook - Christopher Allman-Bradshaw - TO ANNOUNCE FIRST QUARTER FINANCIAL RESULTS ON APRIL 28, 2022īURLINGTON, N.C., MaLabcorp (NYSE: LH), a leading global life sciences company, will release its financial results for the first quarter of 2022 before the market opens on Thursday, April 28, 2022.
0 Comments
Leave a Reply. |
AuthorWrite something about yourself. No need to be fancy, just an overview. ArchivesCategories |